Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma
The Oncologist · 2025
DOI: 10.1093/oncolo/oyae260 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Oncologist, 2025. Verfasst von Bixia Tang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Soft Tissue Sarcoma, Peking U…. Hauptthemen laut MEDLINE: Albumins, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Oncology Pharmaceutical Limited.
Abstract (Originalsprache)
Background
PD-1/PD-L1 immune checkpoint inhibitors (ICIs) have demonstrated activity in the post-platinum and platinum-ineligible settings for advanced urothelial carcinoma (aUC). As only around 50% of patients with aUC can tolerate platinum-containing treatment, treatments combining first-line ICIs with non-platinum drugs are urgently needed. Therefore, we assessed the safety and efficacy of the anti-PD-L1 monoclonal antibody Socazolimab in combination with nab-paclitaxel as first-line therapy in aUC (NCT04603846).
Methods
This was a multi-center, single-arm, phase Ib study that enrolled patients with treatment-naive aUC. Patients received Socazolimab (5 mg/kg) and nab-paclitaxel (260 mg/m2) Q3w. The primary endpoint was safety and tolerability of the combination regimen. Second endpoints were the objective response rate (ORR) and progression-free survival.
Results
Between September, 2020 and September, 2021, 20 patients with urothelial carcinoma were enrolled, arising from renal pelvis (5), bladder (8), and ureter (7). After a median follow-up of 17 months, the median number of treatment cycles was 12. No patients had dose limiting toxicity. All patients had treatment-related adverse events (TRAEs), most of which were grade 1 or 2. The common TRAEs (≥20%) were peripheral neurotoxicity, alopecia, rash, increased ALT, weight loss, weakness, pruritus, increased AST, increased γGT, increased ALP, neutropenia, emesis, and anorexia. Nine patients (45%) developed grade 3 TRAEs including peripheral neurotoxicity (30.0%), increased ALT (10.0%), and increased γGT (5.0%). Two patients (10%) discontinued treatment because of grade 3 mouth ulcer (n = 1) and grade 2 lung fibrosis (n = 1). No grade 4-5 TRAEs were observed. Among the 17 patients who had received at least one tumor assessment, ORR was 58.8% (95% CI, 32.9%-81.6%) and the median progression-free survival was 8.3 months (95% CI, 5.2-19.5). The median duration of response was 13.3 months (95% CI, 2.0-20.1), and the overall survival was 19.5 months (95% CI, 11.2-not reached).
Conclusion
Socazolimab combined with nab-paclitaxel has shown good safety and promising antitumor activity as first-line therapy in patients with advanced urothelial carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Soft Tissue Sarcoma, Peking University Cancer Hospital & Institute, Beijing, People's Republic of C…
- Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
- Zhaoke (Guangzhou) Oncology Pharmaceutical Limited, Guangzhou 511400, People's Republic of China.
ORCID-Profile: Bixia Tang, Lu Si, Li Zhou, Xinan Sheng
Förderung
- Oncology Pharmaceutical Limited
Zitieren
APA
Tang, B., Xiao, J., Chi, Z., Duan, R., Cui, C., Si, L., Liu, Y., Hu, X., Liu, Z., Xiang, P., Li, S., Yan, X., Zhou, L., Li, J., Li, Y., Yu, X., Dai, X., Li, X., Guo, J., & Sheng, X. (2025). Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyae260
Vancouver
Tang B, Xiao J, Chi Z, Duan R, Cui C, Si L, et al. Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma. The Oncologist. 2025. doi:10.1093/oncolo/oyae260
BibTeX
@article{Tang2025,
author = {Tang, Bixia and Xiao, Jun and Chi, Zhihong and Duan, Rong and Cui, Chuanliang and Si, Lu and Liu, Yixun and Hu, Xuechun and Liu, Zhi and Xiang, Ping and Li, Siming and Yan, Xieqiao and Zhou, Li and Li, Juan and Li, Yujie and Yu, Xiaohui and Dai, Xiangrong and Li, Xiaoyi and Guo, Jun and Sheng, Xinan},
title = {Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyae260}
}
EUVIMED